About Cordance Medical

Cordance Medical is developing the NeuroAccess™ system, a non-invasive ultrasound device that reversibly opens the blood-brain barrier using low-frequency focused ultrasound and microbubbles. This technology enables targeted delivery of therapeutics and diagnostic biomarkers to the brain, addressing the challenge of drug delivery for conditions such as brain cancers, Alzheimer's, and Parkinson's disease.

```xml <problem> The blood-brain barrier (BBB) prevents effective drug delivery and biomarker measurement for brain diseases, hindering the treatment of conditions like brain cancers, Alzheimer's, Parkinson's, and Epilepsy. Current methods struggle to overcome this barrier, limiting therapeutic options and diagnostic capabilities. </problem> <solution> Cordance Medical is developing the NeuroAccess™ system, a non-invasive ultrasound device designed to reversibly open the blood-brain barrier. The system uses low-frequency focused ultrasound and microbubbles to temporarily disrupt the BBB, enabling targeted delivery of therapeutics and diagnostic biomarkers to specific areas of the brain. This approach aims to improve treatment efficacy for brain cancers, Alzheimer's, Parkinson's, and Epilepsy by allowing drugs to reach the affected tissues and enabling blood tests for disease diagnosis and tracking. The NeuroAccess™ system facilitates precision medicine by providing a patient-friendly and repeatable method for accessing the brain. </solution> <features> - Non-invasive BBB opening using low-frequency focused ultrasound and microbubbles - Targeted drug delivery to specific brain regions - Enables blood tests for diagnostic biomarker measurement - Reversible BBB opening for repeatable treatments - Patient-friendly design suitable for outpatient settings - Approved patent and multiple pending patents related to the device and its applications </features> <target_audience> The primary target audience includes patients with brain cancers, Alzheimer's, Parkinson's, and Epilepsy, as well as clinicians and pharmaceutical companies focused on developing and delivering therapies for these conditions. </target_audience> ```

What does Cordance Medical do?

Where is Cordance Medical located?

Cordance Medical is based in Mountain View, United States.

When was Cordance Medical founded?

Cordance Medical was founded in 2018.

How much funding has Cordance Medical raised?

Cordance Medical has raised 12250000.

Location

Mountain View, United States

Founded

2018

Funding

12250000

Employees

10 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Cordance Medical

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

cordancemedical.com 700+

Crunchbase

Founded 2018 – Mountain View, United States

Funding

Estimated Funding

$10M+

Team (10+)

No team information available.

Company Description

Problem

The blood-brain barrier (BBB) prevents effective drug delivery and biomarker measurement for brain diseases, hindering the treatment of conditions like brain cancers, Alzheimer's, Parkinson's, and Epilepsy. Current methods struggle to overcome this barrier, limiting therapeutic options and diagnostic capabilities.

Solution

Cordance Medical is developing the NeuroAccess™ system, a non-invasive ultrasound device designed to reversibly open the blood-brain barrier. The system uses low-frequency focused ultrasound and microbubbles to temporarily disrupt the BBB, enabling targeted delivery of therapeutics and diagnostic biomarkers to specific areas of the brain. This approach aims to improve treatment efficacy for brain cancers, Alzheimer's, Parkinson's, and Epilepsy by allowing drugs to reach the affected tissues and enabling blood tests for disease diagnosis and tracking. The NeuroAccess™ system facilitates precision medicine by providing a patient-friendly and repeatable method for accessing the brain.

Features

Non-invasive BBB opening using low-frequency focused ultrasound and microbubbles

Targeted drug delivery to specific brain regions

Enables blood tests for diagnostic biomarker measurement

Reversible BBB opening for repeatable treatments

Patient-friendly design suitable for outpatient settings

Approved patent and multiple pending patents related to the device and its applications

Target Audience

The primary target audience includes patients with brain cancers, Alzheimer's, Parkinson's, and Epilepsy, as well as clinicians and pharmaceutical companies focused on developing and delivering therapies for these conditions.